5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICA-riboside) as a targeting agent for therapy of patients with acute lymphoblastic leukemia: are we there and are there pitfalls?
Cronstein
Bruce N
BN
NYU School of Medicine, New York, New York, USA.
Kamen
Barton A
BA
D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D002648:Child; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D012263:Ribonucleosides / Q000627:therapeutic use* / Q000633:toxicity*
D000970:Antineoplastic Agents; D012263:Ribonucleosides; D000620:Aminoimidazole Carboxamide; C011651:acadesine